IL-27 AS EFFECTOR MOLECULE IN VIRAL INFECTIONS AND IMMUNITY



Cite item

Full Text

Abstract

Abstract

Interleukin-27 (IL-27) is a cytokine with multifaceted effects on immune responses. It is composed of two subunits: IL-27p28 and IL-6. The receptor complex for IL-27 consists of the heterodimeric IL-27R, which includes IL-27Rα and gp130. This receptor is expressed on various cell types, including T lymphocytes, B cells, NK cells, dendritic cells, macrophages, as well as endothelial and epithelial cells. Initially, IL-27 was primarily associated with Th1-mediated immune responses, but it is now recognized to also exhibit anti-inflammatory functions. IL-27 is mainly produced by antigen-presenting cells, such as dendritic cells and macrophages, but can also be secreted by adaptive immune cells. Its production is linked to infectious and autoimmune processes. The key effects of this cytokine include: direct modulation of effector CD4+ and CD8+ T-cell functions, stimulation of anti-inflammatory IL-10 production, recruitment of specialized regulatory T cells (Treg). In vitro, IL-27 promotes the proliferation of naïve CD4+ T lymphocytes through simultaneous binding to CD3 and the T-cell receptor. Additionally, this cytokine enhances CD4+ T-cell mobilization by increasing the secretion of chemokines and adhesion molecules. At the same time, IL-27 exerts anti-inflammatory effects, particularly by suppressing Th17-mediated immune responses. Despite its dual functionality, IL-27 is frequently associated with the progression of infectious processes in in vitro experiments and murine models. It serves as a crucial modulator of immune responses, capable of both activating protective mechanisms and restraining excessive inflammation. This study, based on literature data and the personal findings, highlights the diverse roles of IL-27 in viral infections such as influenza, HIV, COVID-19, and hepatitis B and C. The potential of IL-27 as a laboratory marker for clinical progression of viral infections remains to be fully elucidated. Its levels in peripheral blood are influenced by multiple factors, including the presence or absence of comorbidities. Thus, IL-27 is a key cytokine involved in the immunopathogenesis of viral infections. Investigating its diagnostic and differential significance in the aforementioned conditions may become a relevant scientific challenge.

About the authors

Zoia R. Korobova

Saint Petersburg Pasteur Institute;
Pavlov First State Medical University of St. Petersburg

Email: zoia-korobova@yandex.ru
ORCID iD: 0000-0003-0535-5014

Junior Researcher

Россия, Saint Petersburg, Russia, Mira 14

Natalia A. Arsentieva

Saint Petersburg Pasteur Institute;
Pavlov First State Medical University of St. Petersburg

Email: arsentieva_n.a@bk.ru
ORCID iD: 0000-0003-2490-308X

PhD (Biology), Senior Researcher, Laboratory of Molecular Immunology

Россия, Saint Petersburg, Russia, Mira 14

Areg A. Totolian

Saint Petersburg Pasteur Institute;
Pavlov First State Medical University of St. Petersburg

Author for correspondence.
Email: zoia-korobova@yandex.ru

RAS Full Member, DSc (Medicine), Professor, Director, Head of the Department of Immunology

Россия, 197101, St. Petersburg, Mira str., 14; St. Petersburg

References

  1. Арсентьева Н.А., Бацунов О.К., Любимова Н.Е., Басина В.В., Эсауленко Е.В., Тотолян А.А. Профиль цитокинов плазмы крови больных хроническим вирусным гепатитом С // Медицинская иммунология. 2024. Т. 26, № 6. С. 1235–1248. Arsentieva N.A., Batsunov O.K., Lyubimova N.E., Basina V.V., Esaulenko E.V., Totolian A.A. Cytokine profiling of plasma in patients with viral hepatitis C. Medical Immunology (Russia). 2024;26(6):1235-1248. (In Russ.) https://doi.org/10.15789/1563-0625-CPO-3117
  2. Арсентьева Н.А., Любимова Н.Е., Бацунов О.К., Коробова З.Р., Станевич О.В., Лебедева А.А. и др. Цитокины в плазме крови больных COVID-19 в острой фазе заболевания и фазе полного выздоровления // Медицинская иммунология. 2021. Т. 23, № 2. С. 311–326. Arsentieva N.A., Liubimova N.E., Batsunov O.K., Korobova Z.R., Stanevich O.V., Lebedeva A.A., Vorobyov E.A., Vorobyova S.V., Kulikov A.N., Lioznov D.A., Sharapova M.A., Pevtcov D.E., Totolian A.A. Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery. Medical Immunology (Russia). 2021;23(2):311-326. (In Russ.) https://doi.org/10.15789/1563-0625-PCI-2312
  3. Бацунов О.К., Арсентьева Н.А., Любимова Н.Е., Зыонг Дык Чонг, Басина В.В., Эсауленко Е.В., Тотолян А.А. Оценка уровня цитокинов в плазме крови больных хроническим вирусным гепатитом В на различных стадиях фиброза печени // Медицинская иммунология. 2025. Принято в печать. - -
  4. Arsentieva N.A., Lyubimova N.E., Batsunov O.K., Korobova Z.R., Stanevich O.V., Lebedeva A.A. et al. Plasma cytokines in acute and convalescent COVID-19 patients. Medical Immunology. 2021. Vol. 23, no. 2. Pp. 311–326. - https://doi.org/10.15789/1563-0625-PCI-2312
  5. Amsden H., Kourko O., Roth M., Gee K. Antiviral Activities of Interleukin-27: A Partner for Interferons? // Frontiers in Immunology. 2022. Vol. 13. Art. 902853 - https://doi.org/10.3389/fimmu.2022.902853
  6. Andres-Martin F., James C., Catalfamo M. IL-27 expression regulation and its effects on adaptive immunity against viruses // Frontiers in Immunology. 2024. Vol. 15. Art. 1395921. - https://doi.org/10.3389/fimmu.2024.1395921.
  7. Clement M., Marsden M., Stacey M.A. et al. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence // PLoS Pathogens. 2016. Vol. 12, no. 11. Art. e1006050. - https://doi.org/10.1371/journal.ppat.1006050
  8. Devergne O., Hummel M., Koeppen H. et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes // Journal of Virology. 1996. Vol. 70, no. 2. Pp. 1143–1153. - https://doi.org/10.1128/jvi.70.2.1143-1153.1996.
  9. Fan J., Zhang Y.C., Zheng D.F. et al. IL-27 is elevated in sepsis with acute hepatic injury and promotes hepatic damage and inflammation in the CLP model // Cytokine. 2020. Vol. 127. Art. 154936. - https://doi.org/10.1016/j.cyto.2019.154936
  11. Forrester M.A., Robertson L., Bayoumi N. et al. Human interleukin-27: wide individual variation in plasma levels and complex inter-relationships with interleukin-17A // Clinical and Experimental Immunology. 2014. Vol. 178, no. 2. Pp. 373–383 - https://doi.org/10.1111/cei.12408.
  12. Frank A.C., Zhang X., Katsounas A. et al. Interleukin-27, an Anti-HIV-1 Cytokine, Inhibits Replication of Hepatitis C Virus // Journal of Interferon & Cytokine Research. 2010. Vol. 30, no. 6. Pp. 427–431. - https://doi.org/10.1089/jir.2009.0093
  13. Hamdy H., Elhamammy R.H., Abdelmageed M., Wahid A. Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients // Virology Journal. 2025. Vol. 22, no. 1. Art. 66. - https://doi.org/10.1186/s12985-025-02668-z.
  14. Hanna W.J., Berrens Z., Langner T. et al. Interleukin-27: a novel biomarker in predicting bacterial infection among the critically ill // Critical Care. 2015. Vol. 19. Art. 378. - https://doi.org/10.1186/s13054-015-1095-2
  15. Jouhault Q., Cherqaoui B., Jobart-Malfait A. et al. Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses // Frontiers in Immunology. 2023. Vol. 13. Art. 1072420. - https://doi.org/10.3389/fimmu.2022.1072420
  16. Klingler J., Lambert G.S., Bandres J.C. et al. Immune Profiles to Distinguish Hospitalized versus Ambulatory COVID-19 Cases in Older Patients // iScience. 2022. Vol. 25. Art. 105608. - https://doi.org/10.1016/j.isci.2022.105608
  17. Koltsova E.K., Kim G., Lloyd K.M. et al. Interleukin-27 receptor limits atherosclerosis in Ldlr−/− mice // Circulation Research. 2012. Vol. 111, no. 10. Pp. 1274–1285. - https://doi.org/10.1161/CIRCRESAHA.112.277525
  18. Korobova Z.R., Arsentieva N.A., Lyubimova N.E. et al. Cytokine profiling in SARS-CoV-2 genetic variants. International Journal of Molecular Sciences. 2022. Vol. 23. P. 14146.
  19. - https://doi.org/10.3390/ijms232214146
  20. Korobova Z.R., Arsentieva N.A., Santoni A., Totolian A.A. Role of IL-27 in COVID-19: A Thin Line between Protection and Disease Promotion // International Journal of Molecular Sciences. 2024. Vol. 25, no. 14. Art. 7953. - https://doi.org/10.3390/ijms25147953.
  21. Kudryavtsev I.V., Arsentieva N.A., Korobova Z.R. et al. Heterogenous CD8+ T Cell Maturation and ‘Polarization’ in Acute and Convalescent COVID-19 Patients // Viruses. 2022. Vol. 14, no. 9. Art. 1906. - https://doi.org/10.3390/v14091906
  22. Kumar P., Rajasekaran K., Nanbakhsh A. et al. IL-27 Promotes NK Cell Effector Functions via MAF-NRF2 Pathway During Influenza Infection // Scientific Reports. 2019. Vol. 9, no. 1. Art. 4984. - https://doi.org/10.1038/s41598-019-41478-6
  23. Liu F.D., Kenngott E.E., Schroter M.F. et al. Timed action of IL-27 protects from immunopathology while preserving defense in influenza // PLoS Pathogens. 2014. Vol. 10, no. 5. Art. e1004110. - https://doi.org/10.1371/journal.ppat.1004110.
  24. Liu L., Cao Z., Chen J. et al. Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling // Journal of Biological Chemistry. 2012. Vol. 287, no. 15. Pp. 11899–11910. -
  25. https://doi.org/10.1074/jbc.M111.308064.
  26. Martin E., Winter S., Garcin C. et al. Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency // Nature. 2024. Vol. 628. Pp. 620–629 - https://doi.org/10.1038/s41586-024-07213-6
  27. Mei Y., Lv Z., Xiong L. et al. The dual role of IL-27 in CD4+ T cells // Molecular Immunology. 2021. Vol. 138. Pp. 172–180. - https://doi.org/10.1016/j.molimm.2021.08.00
  28. Naya A., Bouklouze A., Zaid Y., Naciri M. Explanatory Predictive Model for COVID-19 Severity Risk Employing Machine Learning, Shapley Addition, and LIME // Scientific Reports. 2023. Vol. 13. Art. 1–19. - https://doi.org/10.1038/s41598-023-36489-3.
  29. Petes C., Odoardi N., Plater S.M. et al. IL-27 amplifies cytokine responses to Gram-negative bacterial products and Salmonella typhimurium infection // Scientific Reports. 2018. Vol. 8. Art. 13704. - https://doi.org/10.1038/s41598-018-32007-y.
  30. Pflanz S., Timans J.C., Cheung J. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells // Immunity. 2002. Vol. 16, no. 6. Pp. 779–790. - https://doi.org/10.1016/S1074-7613(02)00324-2
  31. Poudyal D., Yang J., Chen Q. et al. IL-27 posttranslationally regulates Y-box binding protein-1 to inhibit HIV-1 replication in human CD4+ T cells // AIDS. 2019. Vol. 33, no. 12. Pp. 1819–1830. - https://doi.org/10.1097/QAD.0000000000002288
  32. Ramamurthy N., Boninsegna S., Adams R. et al. Impact of IL-27 on hepatocyte antiviral gene expression and function // Wellcome Open Research. 2016. Vol. 1. Art. 17. - https://doi.org/10.12688/wellcomeopenres.9917.1
  33. Robinson K.M., Lee B., Scheller E.V. et al. The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia // Respiratory Research. 2015. Vol. 16. Art. 10. - https://doi.org/10.1186/s12931-015-0168-8
  34. Seman B.G., Vance J.K., Rawson T.W. et al. Elevated Levels of Interleukin-27 in Early Life Compromise Protective Immunity in a Mouse Model of Gram-Negative Neonatal Sepsis // Infection and Immunity. 2020. Vol. 88, no. 3. Art. e00828-19 - https://doi.org/10.1128/IAI.00828-19
  35. Shaoju Qian, Xingyi Zhang, Xiaoxiao Zheng et al. Development of interleukin-27 recombinant Lactococcus lactis and its efficacy in treating psoriasis and colitis in mice // International Journal of Biological Macromolecules. 2024. Vol. 282. Art. 137113. - https://doi.org/10.1016/j.ijbiomac.2024.137113
  36. Swaminathan S., Dai L., Lane H.C., Imamichi T. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection // Cytokine & Growth Factor Reviews. 2013. Vol. 24, no. 6. Pp. 571–577. - https://doi.org/10.1016/j.cytogfr.2013.07.
  37. Valdés-López J.F., Urcuqui-Inchima S. Antiviral Response and Immunopathogenesis of Interleukin 27 in COVID-19 // Archives of Virology. 2023. Vol. 168. Pp. 1–19. - https://doi.org/10.1007/s00705-023-05772-7
  38. Wang H.-L., Zhang H.-Y., Zhai Z.-L., Zhou X. The correlation between hepatitis B virus infection and IL-27 // Bio-Medical Materials and Engineering. 2012. Vol. 22, no. 1–3. Pp. 187–193. - https://doi.org/10.3233/BME-2012-0706
  39. Wang X., Liu X., Zhang Y. et al. Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice // Clinical and Experimental Immunology. 2016. Vol. 186, no. 2. Pp. 144–156. - https://doi.org/10.1111/cei.12840.
  40. Wehrens E.J., Wong K.A., Gupta A. et al. IL-27 regulates the number, function and cytotoxic program of antiviral CD4 T cells and promotes cytomegalovirus persistence // PLoS ONE. 2018. Vol. 13, no. 7. Art. e0201249 - https://doi.org/10.1371/journal.pone.0201249.
  41. Yoshida H., Hunter C.A. The immunobiology of interleukin-27 // Annual Review of Immunology. 2015. Vol. 33. Pp. 417–443. - https://doi.org/10.1146/annurev-immunol-032414-112134.
  42. Yoshitaka Hosokawa, Ikuko Hosokawa, Kazumi Ozaki, Takashi Matsuo. IL-27 Modulates Chemokine Production in TNF-α-Stimulated Human Oral Epithelial Cells // Cellular Physiology and Biochemistry. 2017. Vol. 43, no. 3. Pp. 1198–1206 -
  43. https://doi.org/10.1159/000481760
  44. Zamani B., Najafizadeh M., Motedayyen H., ArefNezhad R. Predicting Roles of IL-27 and IL-32 in Determining the Severity and Outcome of COVID-19 // International Journal of Immunopathology and Pharmacology. 2022. Vol. 36. Art. 03946320221145827 - https://doi.org/10.1177/03946320221145827
  45. Zhu C., Zhang R., Liu L. et al. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro // Clinical Immunology. 2009. Vol. 131, no. 1. Pp. 92–97. - https://doi.org/10.1016/j.clim.2008.10.011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Korobova Z.R., Arsentieva N.A., Totolian A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies